1-9 of 9
Paola Secchiero
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Editor's Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

Giorgio Zauli, Rebecca Voltan, Raffaella Bosco, Elisabetta Melloni, Sandra Marmiroli, Gian Matteo Rigolin, Antonio Cuneo, Paola Secchiero
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2972.
https://doi.org/10.1158/1078-0432.CCR-22-1596
Published: 01 July 2022
View article titled, Editor's Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53<sup>wild-type</sup> and p53<sup>mutated</sup> B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
Open the PDF for Editor's Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53<sup>wild-type</sup> and p53<sup>mutated</sup> B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway in another window
Journal Articles

Editor's Note: Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts

Rebecca Voltan, Paola Secchiero, Barbara Ruozi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, Giorgio Zauli
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2971.
https://doi.org/10.1158/1078-0432.CCR-22-1597
Published: 01 July 2022
View article titled, Editor's Note: Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Open the PDF for Editor's Note: Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts in another window
Journal Articles

Editor's Note: The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by Both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells

Paola Secchiero, Rebecca Voltan, Maria Grazia di Iasio, Elisabetta Melloni, Mario Tiribelli, Giorgio Zauli
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2973.
https://doi.org/10.1158/1078-0432.CCR-22-1595
Published: 01 July 2022
View article titled, Editor's Note: The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by Both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells
Open the PDF for Editor's Note: The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by Both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells in another window
Journal Articles

Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts

Rebecca Voltan, Paola Secchiero, Barbara Ruozi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, Giorgio Zauli
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3871–3880.
https://doi.org/10.1158/1078-0432.CCR-13-0015
Published: 15 July 2013
View article titled, Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Open the PDF for Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts in another window
Includes: Supplementary data
Journal Articles

C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway

Paola Secchiero, Erika Rimondi, Maria Grazia di Iasio, Chiara Agnoletto, Elisabetta Melloni, Ilaria Volpi, Giorgio Zauli
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 1949–1959.
https://doi.org/10.1158/1078-0432.CCR-12-3027
Published: 15 April 2013
View article titled, C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway
Open the PDF for C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway in another window
Includes: Supplementary data
Journal Articles

Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells

Rebecca Voltan, Maria Grazia di Iasio, Raffaella Bosco, Nicola Valeri, Yuri Pekarski, Mario Tiribelli, Paola Secchiero, Giorgio Zauli
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5649–5655.
https://doi.org/10.1158/1078-0432.CCR-11-1064
Published: 01 September 2011
View article titled, Nutlin-3 Downregulates the Expression of the Oncogene <em>TCL1</em> in Primary B Chronic Lymphocytic Leukemic Cells
Open the PDF for Nutlin-3 Downregulates the Expression of the Oncogene <em>TCL1</em> in Primary B Chronic Lymphocytic Leukemic Cells in another window
Includes: Supplementary data
Journal Articles

miR-34a Induces the Downregulation of Both E2F1 and B-Myb Oncogenes in Leukemic Cells

Giorgio Zauli, Rebecca Voltan, Maria Grazia di Iasio, Raffaella Bosco, Elisabetta Melloni, Maria Elena Sana, Paola Secchiero
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2712–2724.
https://doi.org/10.1158/1078-0432.CCR-10-3244
Published: 01 May 2011
View article titled, miR-34a Induces the Downregulation of Both <em>E2F1</em> and <em>B-Myb</em> Oncogenes in Leukemic Cells
Open the PDF for miR-34a Induces the Downregulation of Both <em>E2F1</em> and <em>B-Myb</em> Oncogenes in Leukemic Cells in another window
Includes: Supplementary data
Journal Articles

Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

Giorgio Zauli, Rebecca Voltan, Raffaella Bosco, Elisabetta Melloni, Sandra Marmiroli, Gian Matteo Rigolin, Antonio Cuneo, Paola Secchiero
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 762–770.
https://doi.org/10.1158/1078-0432.CCR-10-2572
Published: 15 February 2011
View article titled, Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53<sup>wild-type</sup> and p53<sup>mutated</sup> B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
Open the PDF for Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53<sup>wild-type</sup> and p53<sup>mutated</sup> B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway in another window
Includes: Supplementary data
Journal Articles

The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells

Paola Secchiero, Rebecca Voltan, Maria Grazia di Iasio, Elisabetta Melloni, Mario Tiribelli, Giorgio Zauli
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1824–1833.
https://doi.org/10.1158/1078-0432.CCR-09-3031
Published: 14 March 2010
View article titled, The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells
Open the PDF for The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells in another window